{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:01:12Z","timestamp":1788519672058,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA258692, CA249087, A158569"],"award-info":[{"award-number":["CA258692, CA249087, A158569"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Introduction Pheochromocytoma (PCC) and paraganglioma (PG) research is limited due to rarity of disease. We utilized patient-derived tumor organoids (PTOs) to explore personalized treatment options for these patients. Tumors were obtained from patients with PCC and PG who underwent operative resection and processed to biofabricate PTOs utilizing a collagen-based hydrogel. Blood was also obtained from patients to generate immune-enhanced PTOs (iPTOs). Organoids underwent treatment with chemotherapy, immunotherapy, or tyrosine kinase inhibitors. Cell viability was determined using multiple assays. Significant treatments demonstrated viability\u2009&lt;\u200950% and p\u2009&lt;\u20090.05 compared to controls. Twelve PCC and 4 PG tumors were obtained from December 2020 \u2013 May 2023. Viable PTOs were generated in 15\/16 (93.8%) tumors for drug studies. Sunitinib (10 \u00b5M) demonstrated significant treatment efficacy in 9\/14 PTOs (64.3%) with average post-treatment viability of 28%. A commonly utilized clinical regimen of cyclophosphamide, vincristine, doxorubicin and dacarbazine (10 \u00b5M) demonstrated significant treatment effect in 3\/7 treated PTOs (42.9%) with average post-treatment viability of 25.5%. Only 1\/13 iPTOs (7.7%) demonstrated sensitivity to Ipilimumab\/Nivolumab. Cultured PTOs produced measurable norepinephrine on ELISA. PTOs are a feasible platform to study PCC and PG and their response to systemic treatments on a personalized level. <\/jats:p>","DOI":"10.1038\/s41598-025-19806-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:04:52Z","timestamp":1760454292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Richard A.","family":"Erali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia R.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Edenhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Meeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian D.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Soker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese W.","family":"Randle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"19806_CR1","first-page":"802","volume":"58","author":"CM Beard","year":"1983","unstructured":"Beard, C. M., Sheps, S. G., Kurland, L. T., Carney, J. A. & Lie, J. T. Occurrence of pheochromocytoma in rochester, minnesota, 1950 through 1979. Mayo Clin. Proc. 58, 802\u2013804 (1983).","journal-title":"Mayo Clin. Proc."},{"key":"19806_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou, A., Kaltsas, G., Ilias, I. & Grossman, A. B. The diagnosis and management of malignant Phaeochromocytoma and paraganglioma. Endocr. Relat. Cancer. 14, 569\u2013585. https:\/\/doi.org\/10.1677\/ERC-07-0074 (2007).","journal-title":"Endocr. Relat. Cancer"},{"key":"19806_CR3","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","volume":"34","author":"S Jasim","year":"2020","unstructured":"Jasim, S. & Jimenez, C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract. Res. Clin. Endocrinol. Metab. 34, 101354. https:\/\/doi.org\/10.1016\/j.beem.2019.101354 (2020).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"19806_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2018","unstructured":"Breen, W. et al. External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv. Radiat. Oncol. 3, 25\u201329. https:\/\/doi.org\/10.1016\/j.adro.2017.11.002 (2018).","journal-title":"Adv. Radiat. Oncol."},{"key":"19806_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2169\/internalmedicine.49.3061","volume":"49","author":"S Hidaka","year":"2010","unstructured":"Hidaka, S. et al. Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE). Intern. Med. 49, 645\u2013651. https:\/\/doi.org\/10.2169\/internalmedicine.49.3061 (2010).","journal-title":"Intern. Med."},{"key":"19806_CR6","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez, M. et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118, 2804\u20132812. https:\/\/doi.org\/10.1002\/cncr.26577 (2012).","journal-title":"Cancer"},{"key":"19806_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang, H. et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113, 2020\u20132028. https:\/\/doi.org\/10.1002\/cncr.23812 (2008).","journal-title":"Cancer"},{"key":"19806_CR8","unstructured":"FDA approves belzutifan for pheochromocytoma or paraganglioma, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma (."},{"key":"19806_CR9","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","volume":"385","author":"J Kamihara","year":"2021","unstructured":"Kamihara, J. et al. Belzutifan, a potent HIF2alpha inhibitor, in the Pacak-Zhuang syndrome. N Engl. J. Med. 385, 2059\u20132065. https:\/\/doi.org\/10.1056\/NEJMoa2110051 (2021).","journal-title":"N Engl. J. Med."},{"key":"19806_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/MED.0000000000000544","volume":"27","author":"C Jimenez","year":"2020","unstructured":"Jimenez, C., Nunez, R. & Wendt, R. High-specific-activity iodine 131 Metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. Curr. Opin. Endocrinol. Diabetes Obes. 27, 162\u2013169. https:\/\/doi.org\/10.1097\/MED.0000000000000544 (2020).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"19806_CR11","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","volume":"27","author":"A Jha","year":"2021","unstructured":"Jha, A. et al. High-Specific-Activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 27, 2989\u20132995. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3703 (2021).","journal-title":"Clin. Cancer Res."},{"key":"19806_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma, D. A. et al. Efficacy and safety of High-Specific-Activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J. Nucl. Med. 60, 623\u2013630. https:\/\/doi.org\/10.2967\/jnumed.118.217463 (2019).","journal-title":"J. Nucl. Med."},{"key":"19806_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2967\/jnumed.124.269121","volume":"66","author":"PJ Gawne","year":"2025","unstructured":"Gawne, P. J. et al. Theranostics for neuroblastoma: making molecular radiotherapy work better. J. Nucl. Med. 66, 490\u2013496. https:\/\/doi.org\/10.2967\/jnumed.124.269121 (2025).","journal-title":"J. Nucl. Med."},{"key":"19806_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai, S., Katabami, T., Tsuiki, M., Tanaka, Y. & Naruse, M. Controlling tumor progression with cyclophosphamide, vincristine, and Dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm. Cancer. 8, 108\u2013118. https:\/\/doi.org\/10.1007\/s12672-017-0284-7 (2017).","journal-title":"Horm. Cancer"},{"key":"19806_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","volume":"189","author":"A Fischer","year":"2023","unstructured":"Fischer, A. et al. Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study. Eur. J. Endocrinol. 189, 546\u2013565. https:\/\/doi.org\/10.1093\/ejendo\/lvad146 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"19806_CR16","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez, M. et al. Treatment with Sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 97, 4040\u20134050. https:\/\/doi.org\/10.1210\/jc.2012-2356 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"19806_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2008.19.9380","volume":"27","author":"NM Hahn","year":"2009","unstructured":"Hahn, N. M. et al. Patient with malignant paraganglioma responding to the multikinase inhibitor Sunitinib malate. J. Clin. Oncol. 27, 460\u2013463. https:\/\/doi.org\/10.1200\/JCO.2008.19.9380 (2009).","journal-title":"J. Clin. Oncol."},{"key":"19806_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2008-1836","volume":"94","author":"AM Joshua","year":"2009","unstructured":"Joshua, A. M. et al. Rationale and evidence for Sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. J. Clin. Endocrinol. Metab. 94, 5\u20139. https:\/\/doi.org\/10.1210\/jc.2008-1836 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"19806_CR19","doi-asserted-by":"publisher","unstructured":"Toledo, R. & Jimenez, C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. F1000Res 7 https:\/\/doi.org\/10.12688\/f1000research.13995.1 (2018).","DOI":"10.12688\/f1000research.13995.1"},{"key":"19806_CR20","doi-asserted-by":"publisher","unstructured":"Gunti, S., Hoke, A. T. K., Vu, K. P. & London, N. R. Jr. Organoid and spheroid tumor models: techniques and applications. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13040874 (2021).","DOI":"10.3390\/cancers13040874"},{"key":"19806_CR21","doi-asserted-by":"publisher","unstructured":"El Harane, S. et al. Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine. Cells 12 (2023). https:\/\/doi.org\/10.3390\/cells12071001","DOI":"10.3390\/cells12071001"},{"key":"19806_CR22","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12089-9","author":"SD Forsythe","year":"2022","unstructured":"Forsythe, S. D., Sivakumar, H., Erali, R. A., Skardal, A. & Votanopoulos, K. I. ASO author reflections: sarcoma organoids: neutralizing the word rare in rare cancers. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-022-12089-9 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"19806_CR23","doi-asserted-by":"publisher","first-page":"13865","DOI":"10.1038\/s41598-022-17921-6","volume":"12","author":"SD Forsythe","year":"2022","unstructured":"Forsythe, S. D. et al. Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. Sci. Rep. 12, 13865. https:\/\/doi.org\/10.1038\/s41598-022-17921-6 (2022).","journal-title":"Sci. Rep."},{"key":"19806_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","volume":"26","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos, K. I. et al. Appendiceal cancer Patient-Specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: A feasibility study. Ann. Surg. Oncol. 26, 139\u2013147. https:\/\/doi.org\/10.1245\/s10434-018-7008-2 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"19806_CR25","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe, S. D. et al. Personalized identification of optimal HIPEC perfusion protocol in Patient-Derived tumor organoid platform. Ann. Surg. Oncol. 27, 4950\u20134960. https:\/\/doi.org\/10.1245\/s10434-020-08790-2 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"19806_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s002800051013","volume":"45","author":"CM Kruijtzer","year":"2000","unstructured":"Kruijtzer, C. M., Beijnen, J. H., Swart, M. & Schellens, J. H. Successful treatment with Paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother. Pharmacol. 45, 428\u2013431. https:\/\/doi.org\/10.1007\/s002800051013 (2000).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"19806_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/pbc.22006","volume":"53","author":"J Mora","year":"2009","unstructured":"Mora, J., Cruz, O., Parareda, A., Sola, T. & de Torres, C. Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatr. Blood Cancer. 53, 663\u2013665. https:\/\/doi.org\/10.1002\/pbc.22006 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"19806_CR28","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1038\/bjc.2014.194","volume":"110","author":"NA Lankheet","year":"2014","unstructured":"Lankheet, N. A. et al. Pharmacokinetically guided Sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br. J. Cancer. 110, 2441\u20132449. https:\/\/doi.org\/10.1038\/bjc.2014.194 (2014).","journal-title":"Br. J. Cancer"},{"key":"19806_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","volume":"13","author":"S Noda","year":"2015","unstructured":"Noda, S. et al. Assessment of Sunitinib-Induced toxicities and clinical outcomes based on therapeutic drug monitoring of Sunitinib for patients with renal cell carcinoma. Clin. Genitourin. Cancer. 13, 350\u2013358. https:\/\/doi.org\/10.1016\/j.clgc.2015.01.007 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"19806_CR30","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","volume":"27","author":"SD Forsythe","year":"2021","unstructured":"Forsythe, S. D. et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study. Clin. Cancer Res. 27, 5141\u20135150. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0982 (2021).","journal-title":"Clin. Cancer Res."},{"key":"19806_CR31","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux, J. et al. SDHB mutations are associated with response to Temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int. J. Cancer. 135, 2711\u20132720. https:\/\/doi.org\/10.1002\/ijc.28913 (2014).","journal-title":"Int. J. Cancer"},{"key":"19806_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson, L. D. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 26, 551\u2013566. https:\/\/doi.org\/10.1097\/00000478-200205000-00002 (2002).","journal-title":"Am. J. Surg. Pathol."},{"key":"19806_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jso.24063","volume":"112","author":"YM Choi","year":"2015","unstructured":"Choi, Y. M. et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J. Surg. Oncol. 112, 815\u2013821. https:\/\/doi.org\/10.1002\/jso.24063 (2015).","journal-title":"J. Surg. Oncol."},{"key":"19806_CR34","doi-asserted-by":"crossref","unstructured":"Wajih, N. et al. Enhancing the Efficacy of HIPEC through Bromelain: A Preclinical Investigation in Appendiceal Cancer. Annals of Surgical Oncology In Press (2024).","DOI":"10.1245\/s10434-024-15355-0"},{"key":"19806_CR35","doi-asserted-by":"publisher","first-page":"11640","DOI":"10.1038\/s41598-023-38545-4","volume":"13","author":"SD Forsythe","year":"2023","unstructured":"Forsythe, S. D. et al. Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform. Sci. Rep. 13, 11640. https:\/\/doi.org\/10.1038\/s41598-023-38545-4 (2023).","journal-title":"Sci. Rep."},{"key":"19806_CR36","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1245\/s10434-022-12086-y","volume":"29","author":"SD Forsythe","year":"2022","unstructured":"Forsythe, S. D. et al. Patient-Specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann. Surg. Oncol. 29, 7354\u20137367. https:\/\/doi.org\/10.1245\/s10434-022-12086-y (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"19806_CR37","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1245\/s10434-019-08143-8","volume":"27","author":"KI Votanopoulos","year":"2020","unstructured":"Votanopoulos, K. I. et al. Model of Patient-Specific Immune-Enhanced organoids for immunotherapy screening: feasibility study. Ann. Surg. Oncol. 27, 1956\u20131967. https:\/\/doi.org\/10.1245\/s10434-019-08143-8 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"19806_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s10439-019-02269-2","volume":"48","author":"S Forsythe","year":"2020","unstructured":"Forsythe, S. et al. Development of a colorectal cancer 3D Micro-tumor construct platform from cell lines and patient tumor biospecimens for Standard-of-Care and experimental drug screening. Ann. Biomed. Eng. 48, 940\u2013952. https:\/\/doi.org\/10.1007\/s10439-019-02269-2 (2020).","journal-title":"Ann. Biomed. Eng."},{"key":"19806_CR39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-022-05096-x","volume":"13","author":"S Bornstein","year":"2022","unstructured":"Bornstein, S. et al. Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin. Cell. Death Dis. 13, 648. https:\/\/doi.org\/10.1038\/s41419-022-05096-x (2022).","journal-title":"Cell. Death Dis."},{"key":"19806_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/ERC-21-0355","volume":"29","author":"K Wang","year":"2022","unstructured":"Wang, K. et al. Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures. Endocr. Relat. Cancer. 29, 285\u2013306. https:\/\/doi.org\/10.1530\/ERC-21-0355 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"19806_CR41","doi-asserted-by":"publisher","first-page":"E1006","DOI":"10.1152\/ajpendo.00156.2012","volume":"303","author":"Y Aita","year":"2012","unstructured":"Aita, Y. et al. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-gamma-related pathways. Am. J. Physiol. Endocrinol. Metab. 303, E1006\u20131014. https:\/\/doi.org\/10.1152\/ajpendo.00156.2012 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"19806_CR42","doi-asserted-by":"publisher","first-page":"1275813","DOI":"10.3389\/fendo.2023.1275813","volume":"14","author":"S Gubbi","year":"2023","unstructured":"Gubbi, S. et al. Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy. Front. Endocrinol. (Lausanne). 14, 1275813. https:\/\/doi.org\/10.3389\/fendo.2023.1275813 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"19806_CR43","doi-asserted-by":"publisher","first-page":"I18","DOI":"10.1161\/01.hyp.7.3_pt_2.i18","volume":"7","author":"HR Keiser","year":"1985","unstructured":"Keiser, H. R., Goldstein, D. S., Wade, J. L., Douglas, F. L. & Averbuch, S. D. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7, I18\u201324. https:\/\/doi.org\/10.1161\/01.hyp.7.3_pt_2.i18 (1985).","journal-title":"Hypertension"},{"key":"19806_CR44","doi-asserted-by":"publisher","unstructured":"Jimenez, C. et al. Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas. Cancers (Basel). 12. https:\/\/doi.org\/10.3390\/cancers12082307 (2020).","DOI":"10.3390\/cancers12082307"},{"key":"19806_CR45","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","volume":"403","author":"E Baudin","year":"2024","unstructured":"Baudin, E. et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 403, 1061\u20131070. https:\/\/doi.org\/10.1016\/S0140-6736(23)02554-0 (2024).","journal-title":"Lancet"},{"key":"19806_CR46","unstructured":"Baudin, E. et al. Annals of Oncology,. in ESMO (2021)."},{"key":"19806_CR47","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1007\/s00268-010-0744-5","volume":"34","author":"A Agarwal","year":"2010","unstructured":"Agarwal, A. et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J. Surg. 34, 3022\u20133028. https:\/\/doi.org\/10.1007\/s00268-010-0744-5 (2010).","journal-title":"World J. Surg."},{"key":"19806_CR48","first-page":"5615","volume":"63","author":"AP Gimenez-Roqueplo","year":"2003","unstructured":"Gimenez-Roqueplo, A. P. et al. Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas. Cancer Res. 63, 5615\u20135621 (2003).","journal-title":"Cancer Res."},{"key":"19806_CR49","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers, F. M. et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J. Clin. Endocrinol. Metab. 91, 4505\u20134509. https:\/\/doi.org\/10.1210\/jc.2006-0423 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"19806_CR50","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-0031-1299707","volume":"44","author":"PF Plouin","year":"2012","unstructured":"Plouin, P. F. et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm. Metab. Res. 44, 390\u2013399. https:\/\/doi.org\/10.1055\/s-0031-1299707 (2012).","journal-title":"Horm. Metab. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19806-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19806-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19806-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T03:25:17Z","timestamp":1760844317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19806-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19806"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19806-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K Votanopoulos is supported by National Institutes of Health R01 grants CA258692, CA249087, A158569 and declares Organoid related patents. This research stems from the Wake Forest Organoids Research Center and was supported by the Wake Forest Comprehensive Cancer Center, Wake Forest Institute for Regenerative Medicine, the Tumor Tissue and Pathology Shared Resource. No other authors declare conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35889"}}